Abstract:123 While transplantation remains the only potentially useful treatment for end-stage organ failure, immunological rejection of allografts continues to be a major problem. We have investigated if the fate of T cell precursors developing in the thymus may be determined by the presence of allo MHC class I peptides, since T cell receptor-MHC class I / self peptide interaction regulates thymocyte development. This study examined the effects and underlying mechanisms of intrathymic (IT) injection of a short segment of a synthetic immunogenic MHC class I peptide [P-2; Residues 67 - 85] of the hypervariable domain of RT1.A derived from WAG rat [RT1u] on islet graft survival in the WF [RT1u]-to-ACI [RT1a]. The results showed that while IT injection of 150 µg P-2 on day -7 did not prolong graft survival in naive recipients [MST of 14.0 days vs 9.6 days in controls], IT injection of 300 µg or 600 µg P-2 led to normoglycemia and permanent islet survival [>200 days] in 4/6 and 3/5 STZ induced diabetic ACI recipients, respectively. IT injection of 150 µg, 300 µg, or 600 µg P-2 combined with 0.5 ml ALS immunosuppression on day -7 led to 100% permanent islet graft survival [>200 days] compared to MST of 15.0 ± 2.3 days in ALS alone treated controls. Similarly prepared animals rejected 3rd party [BN] islets in an acute fashion, thus demonstrating donor specificity. Intravenous injection of 300 µg P-2 combined with 0.5 ml ALS did not prolong islet allografts. The long-term unresponsive islet allograft recipients challenged with 2nd set grafts accepted permanently 4/4 donor-type cardiac allografts while rejecting 3rd party [Lewis] hearts without rejecting the primary [WF] islets. In analyzing the underlying mechanisms of acquired systemic tolerance, we found no suppresser / regulatory cells in the adoptive transfer studies in tolerant animals at 30 days after IT injection of allopeptides. In contrast, adoptive transfer of 5 × 107 unseparated spleen cells or 2 × 107 purified T-cells obtained from tolerant animals 60 and 120 days after islet transplantation into lightly irradiated [200 rad TBI] ACI led to donor-specific permanent islet graft survival in 75 and 100% animals respectively compared to an MST of 14.5 days in lightly irradiated ACI recipients of unmodified syngenic spleen cells. Our findings suggest that maintenance of acquired thymic tolerance induced by class I MHC allopeptides is dependent on generation of regulatory cells and that this strategy may have potential clinical application in the induction of acquired tolerance.

The use of growth factors to modulate the activities of antigen-specific CD8+ T cells in vitro

Efficient And Selective Prevention Of Graft-Versus-Host Disease By Ag-Specific Induced Regulatory T Cells In Mice

REGULATORY T CELLS MAINTAIN PERIPHERAL TOLERANCE TO ISLET ALLOGRAFTS INDUCED BY INTRATHYMIC INJECTION OF MHC CLASS I ALLOPEPTIDES

Molecular mechanisms underlying the modulation of T-cell proliferation and cytotoxicity by immobilized CCL21 and ICAM1

Ex Vivo Expansion of Human Tregs Specific for Alloantigens Presented Directly or Indirectly.

Favorable alteration of tumor microenvironment by immunomodulatory cytokines for efficient T-cell therapy in solid tumors

Transforming Growth Factor-Β1 Influenced the Proliferation and CD25 Expression of Alloreactive T Cells

Modulation of Intracellular Kinase Signaling to Improve TIL Stemness and Function for Adoptive Cell Therapy

CD4+ Th1 cells promote CD8+ Tc1 cell survival, memory response, tumor localization and therapy by targeted delivery of interleukin 2 via acquired pMHC I complexes.

Adoptive T Cell Therapy with IL-12-Preconditioned Low-Avidity T Cells Prevents Exhaustion and Results in Enhanced T Cell Activation, Enhanced Tumor Clearance, and Decreased Risk for Autoimmunity

Pharmacologic HIF stabilization activates costimulatory receptor expression to increase antitumor efficacy of adoptive T cell therapy

Immunotherapeutic strategy based on anti-OX40L and low dose of IL-2 to prolong graft survival in sensitized mice by inducing the generation of CD4+ and CD8+ Tregs

Characterization of Protective Human CD4CD25 FOXP3 Regulatory T Cells Generated with IL-2, TGF-β and Retinoic Acid.

Inhibition of TGF-β signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy

IL-7 + IL-15 are superior to IL-2 for the ex vivo expansion of 4T1 mammary carcinoma-specific T cells with greater efficacy against tumors in vivo

Transfer of Regulatory T Cells Generated Ex Vivo Modifies Graft Rejection Through Induction of Tolerogenic CD4+CD25+ Cells in the Recipient

P38 Inhibition Enhances TCR-T Cell Function and Antagonizes the Immunosuppressive Activity of TGF-β.

Genetic Modification of CD8+ T Cells to Express EGFR: Potential Application for Adoptive T Cell Therapies

Active Cd4(+) Helper T Cells Directly Stimulate Cd8(+) Cytotoxic T Lymphocyte Responses In Wild-Type And Mhc Ii Gene Knockout C57bl/6 Mice And Transgenic Rip-Mova Mice Expressing Islet Beta-Cell Ovalbumin Antigen Leading To Diabetes

New Insights on T Cell Apoptosis in the Induction of Treg-Dependent Dominant Tolerance

Human cell-based artificial antigen-presenting cells for cancer immunotherapy